Onchocerciasis Treatment Market Report 2026

The onchocerciasis treatment market size has grown strongly in recent years. It will grow from $1.11 billion in 2025 to $1.19 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to limited availability of ivermectin and doxycycline in endemic regions, reliance on hospital-based distribution channels, low awareness of onchocerciasis management, inadequate preventive chemotherapy programs, dependency on oral formulations only.

The onchocerciasis treatment market size is expected to see strong growth in the next few years. It will grow to $1.59 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to introduction of moxidectin and long-acting formulations, expansion of online and retail pharmacy distribution, development of combination therapies, increased government and NGO funding for eradication programs, adoption of community-based preventive strategies. Major trends in the forecast period include expansion of mass drug administration (mda) programs, development of pediatric and fixed-dose formulations, increased focus on anti-wolbachia therapies, integration of oral and injectable treatment regimens, growth of community-based and government-supported treatment campaigns.

The growing number of patients experiencing eye-related conditions is anticipated to drive the growth of the onchocerciasis treatment market in the coming years. Eye-associated issues include a wide range of conditions that impact vision and ocular health, such as infections, injuries, and chronic disorders including glaucoma and cataracts. The increase in patients with eye-related issues is mainly attributed to rising screen time and prolonged exposure to digital devices. Onchocerciasis treatment plays a crucial role in preventing and managing vision impairment and blindness by eliminating the parasitic infection responsible for inflammation and damage to eye tissues. For instance, in May 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based public health agency, approximately 20.5 million Americans aged over 40 had cataracts in at least one eye, representing 17.2% of that population, and this number is expected to approach nearly 30 million by 2028. Therefore, the increasing prevalence of eye-related conditions is fueling the growth of the onchocerciasis treatment market.

The increasing demand for surgical procedures is expected to further propel the growth of the onchocerciasis treatment market in the coming years. Surgical procedures are medical interventions performed to remove or repair tissues damaged by disease and are often required when drug therapies are insufficient or when complications pose a risk of long-term harm. This growing demand is driven by the progression of onchocerciasis in certain patients to advanced stages, where surgery becomes necessary to prevent irreversible outcomes such as vision loss or physical disfigurement. Consequently, healthcare systems are expanding surgical capabilities and adopting advanced techniques, which supports overall market growth for onchocerciasis treatment. For instance, in June 2024, according to the International Society of Aesthetic Plastic Surgery (ISAPS), a US-based professional organization representing board-certified aesthetic plastic surgeons, nearly 35 million aesthetic procedures were carried out globally in 2023, reflecting a 3.4% increase from 2022, while surgical procedures rose by 5.5% to over 15.8 million. Therefore, the rising demand for surgical procedures is driving growth in the onchocerciasis treatment market.

Major companies operating in the onchocerciasis treatment market are emphasizing the development of novel antiparasitic drugs to enhance treatment efficacy and shorten therapy duration. Antiparasitic medications are pharmaceutical agents formulated to eliminate or suppress parasites such as worms and protozoa that cause infections in humans. For example, in December 2024, Medicines Development for Global Health (MDGH), an Australia-based non-profit biopharmaceutical organization, received approval from the Ghana Food and Drugs Authority for Moxidectin 2 mg oral tablets to treat river blindness in individuals aged four years and above. This approval allows Ghana to adopt community-based mass drug administration programs using moxidectin, which provides higher efficacy and longer-lasting benefits compared to ivermectin. Through this approval, MDGH aims to expand access to an effective new therapy for onchocerciasis and support large-scale treatment initiatives in endemic regions.

Major companies operating in the onchocerciasis treatment market are Merck & Co. Inc., Teva Pharmaceutical Industries Limited, Hetero Labs Limited, Sun Pharmaceutical Industries Limited, Intas Pharmaceuticals Limited, Dr. Reddy's Laboratories Inc., Cipla Limited, Endo Inc., Lupin Limited, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos - Fundação Oswaldo Cruz (Fiocruz), AMGIS Lifescience Ltd., Drugs for Neglected Diseases initiative (DNDi), Rakshit Drugs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., OREX Pharma Private Limited, Angle Bio Pharma Pvt. Ltd., Senores Pharmaceuticals Inc., Avenacy LLC, Dolphin Pharma, Cerata Pharmaceuticals Inc.

North America was the largest region in the onchocerciasis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onchocerciasis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the onchocerciasis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the onchocerciasis treatment market by increasing the cost of imported active pharmaceutical ingredients (APIs) and finished drug formulations such as ivermectin, doxycycline, and moxidectin. Segments like fixed-dose combination therapies and long-acting oral tablets are particularly affected, with regions in Africa and Asia facing higher import duties. While tariffs have led to higher treatment costs and supply chain adjustments, they also encourage local pharmaceutical production and innovation in formulation development, improving long-term treatment accessibility.

The onchocerciasis treatment market research report is one of a series of new reports that provides onchocerciasis treatment market statistics, including onchocerciasis treatment industry global market size, regional shares, competitors with a onchocerciasis treatment market share, detailed onchocerciasis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the onchocerciasis treatment industry. This onchocerciasis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Onchocerciasis treatment refers to the medical and therapeutic approaches used to control and eliminate infections caused by Onchocerca volvulus, the parasite responsible for river blindness, a disease that mainly affects the skin and eyes. The main objective of treatment is to remove microfilariae (immature larvae) and lower transmission rates, alleviate symptoms, and reduce the risk of vision impairment.

The primary drug types used in onchocerciasis treatment include ivermectin, doxycycline, albendazole, and moxidectin. Ivermectin is an antiparasitic drug widely used to treat several parasitic infections, including onchocerciasis, by destroying the parasite’s larvae (microfilariae). Treatment strategies involve mass drug administration (MDA) and targeted therapy, with routes of administration including oral, injectable, and topical forms. Distribution channels comprise hospital pharmacies, retail pharmacies, and online pharmacies, and the treatments are utilized by end users such as hospitals and clinics, homecare settings, and government and non-governmental programs.

The onchocerciasis treatment market consists of revenues earned by entities providing services such as mass drug administration (MDA) campaigns, community-based health outreach, disease surveillance and diagnostics, vector control initiatives, and public health education. The market value includes the value of related goods sold by the service provider or included within the service offering. The onchocerciasis treatment market also includes sales of antiparasitic drugs, diagnostic kits, drug delivery tools, and protective supplies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.